A case series of immune checkpoint inhibitor-induced gastritis

Athanasia Karavasili; Melina Yerolatsite; George Zarkavelis; Vaia Karafousia; Nanteznta Torounidou; Anna-Lea Amylidi; Eleftherios Kampletsas

doi:10.5114/wo.2025.153801

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2025
vol. 29

Send email

Copy url:

abstract:

Case report

A case series of immune checkpoint inhibitor-induced gastritis

Athanasia Karavasili

¹

,

Melina Yerolatsite

¹

,

George Zarkavelis

^{1, 2}

,

Vaia Karafousia

¹

,

Nanteznta Torounidou

¹

,

Anna-Lea Amylidi

¹

,

Eleftherios Kampletsas

^{1, 2}

Department of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece
Society for Study of Clonal Heterogeneity of Neoplasia (EMEKEN), Ioannina, Greece

Contemp Oncol (Pozn) 2025; 29 (3): 316–319

DOI: https://doi.org/10.5114/wo.2025.153801

Online publish date: 2025/09/16

View full text Get citation

PlumX metrics:

Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of various solid tumors due to their proven efficacy. However, their use is associated with immune-related adverse events (irAEs), which arise from the immune response activated by ICIs. Gastrointestinal irAEs are among the most common and often present as diarrhea or colitis, conditions that can sometimes require discontinuation of ICI therapy. Although irAE gastritis is less frequently reported, it can lead to severe complications, such as gastrorrhagia. Diagnosing immune-related gastritis early can be challenging due to its diverse clinical presentations. While glucocorticoids and other immunosuppressive therapies are standard treatments for irAEs, the optimal management strategy and dosing for immune-related gastritis remain unclear. This case series on gastritis caused by ICI therapy aims to provide clinicians with valuable insights into this complex condition and its management.

keywords:

A case series of immune checkpoint inhibitor-induced gastritis

Athanasia Karavasili 1 , Melina Yerolatsite 1 , George Zarkavelis 1, 2 , Vaia Karafousia 1 , Nanteznta Torounidou 1 , Anna-Lea Amylidi 1 , Eleftherios Kampletsas 1, 2

immunotherapy, gastritis, immune-related side effects

Athanasia Karavasili

¹

,

Melina Yerolatsite

¹

,

George Zarkavelis

^{1, 2}

,

Vaia Karafousia

¹

,

Nanteznta Torounidou

¹

,

Anna-Lea Amylidi

¹

,

Eleftherios Kampletsas

^{1, 2}